Home Cart Sign in  
Chemical Structure| 2230836-55-0 Chemical Structure| 2230836-55-0

Structure of BI-3406
CAS No.: 2230836-55-0

Chemical Structure| 2230836-55-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BI-3406 is a SOS1 inhibitor with IC50 value of 6nM and it exhibits anticancer activity.

Synonyms: SOS1-IN-2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BI-3406

CAS No. :2230836-55-0
Formula : C23H25F3N4O3
M.W : 462.46
SMILES Code : COC1=CC2=C(C(N[C@H](C)C3=CC(C(F)(F)F)=CC(N)=C3)=NC(C)=N2)C=C1O[C@@H]4COCC4
Synonyms :
SOS1-IN-2
MDL No. :MFCD32197204
InChI Key :XVFDNRYZXDHTHT-PXAZEXFGSA-N
Pubchem ID :138911318

Safety of BI-3406

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of BI-3406

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
K562 cells 10, 100, 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
NCI-H358 500 nM 72 hours Evaluate the antiproliferative response of BI-3406 in combination with adagrasib PMC11424490
SW837 1200 nM 144 hours Evaluate the antiproliferative response of BI-3406 in combination with adagrasib PMC11424490
6606PDA cells 10 µM 48 hours To evaluate the synergistic inhibitory effects of BI-3406, trametinib, and BKM120 on the proliferation and cell death of 6606PDA cells. The results showed that the combination of these three drugs significantly reduced BrdU incorporation and synergistically induced cell death. PMC11120498
NCI-H358 cells 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
GP2d cells 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
SW620 cells 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
HPAF-II cells 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
MIA PaCa-2 cells 1000 nmol/L 24 hours To evaluate the degradation ability of SIAIS562055 on SOS1, results showed that SIAIS562055 significantly degraded SOS1 protein. PMC11694061
Bone marrow-derived macrophages 1 μM 4 hours To evaluate the effect of BI-3406 on macrophage gene expression. Results showed that combination treatment significantly decreased Cxcl2 gene expression and increased IL6 and Cx3cr1 expression. PMC10108440

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NCI-H2122 and SW837 xenograft models Oral 50 mg/kg Twice daily for 16 days Evaluate the antitumor effects of BI-3406 in combination with adagrasib PMC11424490
Mouse DhhCre;Nf1fl/fl mice Oral gavage 50 mg/kg Twice daily for 58 days To evaluate the effect of BI-3406 alone or in combination with selumetinib on neurofibroma growth. Results showed that combination therapy significantly reduced tumor volume and cell proliferation and altered macrophage morphology and activation status in the tumor microenvironment. PMC10108440
C57BL/6J mice Pancreatic ductal adenocarcinoma (PDAC) model Oral gavage 50 mg/kg (twice daily) From day 4 to day 36, using a 5-days on/2-days off dosing scheme To evaluate the efficacy and potential adverse side effects of the combination of BI-3406, trametinib, and BKM120 in a PDAC model. The results showed that the combinatorial therapy significantly reduced tumor weight in male mice but had a weaker effect in female mice. Additionally, the therapy showed a higher therapeutic response in male mice. PMC11120498

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.81mL

2.16mL

1.08mL

21.62mL

4.32mL

2.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories